Rua approves debt facility to accelerate sales.

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com





FOR PUBLIC RELEASE

NZX Limited
Wellington

13 May 2025

Rua Bioscience approves debt loan facility to accelerate sales growth.

The Board of Rua Bioscience have approved a debt facility offered to wholesale lenders
for the purchase of stock to accelerate sales growth. As Rua Bioscience expands
globally, the requirements for working capital has increased. This facility provides for up
to $2mill additional working capital for the purchase of inventory for significant sales
growth.

As part of this facility, the Board has resolved to issue up to 5% of the shares on issue as
Warrants to subscribe for fully paid ordinary shares of Rua.

Key terms of the Warrant issue are as follows:

Number of Warrants
Up to a maximum of 11,182,401 warrants for a maximum
$2mill debt facility.
Exercise Price
$0.015 per fully paid ordinary share to be issued on
exercise of each Warrant.
Vesting Date 12 months following Commencement Date
Maturity Date 3 years following Commencement Date
Exercise Period
Warrants are exercisable at any time following Vesting
Date and prior to Maturity Date.
Other Warrants are not to be quoted or tradeable/transferrable.

The Warrants will be issued to wholesale lenders identified by the Board, with the issue
and allotment to occur as funds are made available to Rua.

Strategic alignment with growth objectives

CORPORATE ACTION

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
This debt facility is a pivotal part of Rua growth strategy, aimed at accelerating its
market penetration and significantly scaling revenues. By securing flexible working
capital, Rua is reinforcing its ability to meet the rising demand for its medicinal cannabis
products across domestic and international markets.

ENDS  
 
The person who authorised this announcement:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154

---

Corporate Action Notice

Page 1 of 3

Section 1: Issuer information
Name of issuer Rua Bioscience Limited
Class of Financial Product Ordinary shares
NZX ticker code RUA
ISIN (If unknown, check on NZX
website)
NZRUAE0004S1
Name of Registry Computershare Investor Services Limited
Type of corporate action
(Please mark with an X in the relevant
box/es)
Share Purchase
Plan/retail offer
Renounceable
Rights issue or
Accelerated
Offer

Capital
reconstruction
Non-
Renounceable
Rights issue or
Accelerated
Offer

Call Bonus issue
Placement x
Record date NA
Ex Date (one business day before the
Record Date)
NA
Currency NZD
External approvals required before offer
can proceed on an unconditional basis?
No
Details of approvals required NA
Section 7: Placement
Number of Equity Securities to be
issued
Up to a maximum of 11,182,401 warrants to be converted
at one ordinary share per warrant.

Issue price per Equity Security No consideration is payable for the warrants. Cash
consideration of $0.015 per share is payable on exercise
of the warrants
Maximum dollar amount of Equity
Securities to be issued
1

Up to a maximum $167,736
Proposed issue date This will be variable depending on when lenders are
finally accepted.

1

Where the issue price per Equity Security is not fixed, and the number of Equity Securities to be issued is not known, the Issuer
should instead indicate the maximum dollar amount of Equity Securities to be issued.

2 of 3
Warrants will be issued on the Commencement Date of
each loan agreement with each lender.
Vesting will occur 12 months following the
Commencement Date after which the warrants are able to
be converted to ordinary shares up to the Maturity Date
which is 3 years following the Commencement Date.
Existing holders eligible to
participate
2

Y (limited)
Related Parties eligible to
participate
3

Y
Basis upon which participation by
existing Equity Security holders will
be determined
Lenders will be selected by the Company and must be
wholesale investors or persons who fit within another
relevant exclusion under schedule 1 of the Financial
Markets Act 2013.
Purpose(s) for which the Issuer is
issuing the Equity Securities
The warrants will be issued as part of a Debt Facility
arrangement.
Reason for placement rather than a
pro-rata rights issue or an offer
under a Share Purchase Plan in
which the Issuer’s existing Equity
Security holders would have been
eligible to participate
The warrants are issued as part of a Debt Facility
arrangement whereby the company is seeking funds to
purchase inventory to increase sales. The warrants are
offered as an incentive to lenders.
Equity Securities to be issued
subject to voluntary escrow
No
Number and class of Equity
Securities to be issued that will be
subject to voluntary escrow and the
date from which they will cease to
be escrowed
NA
Section 8: Lead Manager and Underwriter
Lead Manager(s) appointed Y
Name of Lead Manager(s) Northington Partners Limited
Fees, commission or other
consideration payable to Lead
Manager(s) for acting as lead
manager(s)
Nil
Underwritten NA
Name of Underwriter(s) NA

2
Issuers should answer Y if existing shareholders are eligible to participate even if their participation is subject to satisfaction of
eligibility criteria applying to the placement generally, such as the offer only being made to investors in certain jurisdictions or with a
certain status, such as wholesale, sophisticated or professional investors only.

3
Issuers should answer Y if there are no restrictions on participation by Related Parties as a result of their status as Related Parties
(i.e. restrictions on participation applying to the placement generally should be disregarded).

3 of 3
Extent of underwriting (i.e. amount
or proportion of the offer that is
underwritten)
NA
Fees, commission or other
consideration payable to
Underwriter(s) for acting as
underwriter(s)
NA
Summary of significant events that
could lead to the underwriting
being terminated
NA
Section 9: Authority for this announcement
Name of person authorised to make this
announcement
Paul Naske
Contact person for this announcement Paul Naske
Contact phone number 021 445 154
Contact email address paul.naske@ruabio.com
Date of release through MAP 13/5/2025